Back to search
FDAFDA · Food and drugs·Recall number D-0281-2022

Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL glass bottles, Rx Only, Teligent Pharma Inc., Buena, NJ 08310, NDC 52565-009-50

Published December 22, 2021 · Recall initiated: October 12, 2021

Summary

FDA records drug Class II recall D-0281-2022, published December 22, 2021 and initiated October 12, 2021. Recalling firm: Teligent Pharma, Inc.; Status: Terminated; Reported quantity: 14,664 glass bottles; Lot: Lot #: 13058, Exp. date 02/2022 and 13768, Exp. date 05/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teligent Pharma, Inc.
Distributor
Nationwide within the United States
Lot
Lot #: 13058, Exp. date 02/2022 and 13768, Exp. date 05/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL glass bottles, Rx Only, Teligent Pharma Inc., Buena, NJ 08310, NDC 52565-009-50 recalled?

Yes. FDA published recall D-0281-2022 on December 22, 2021. Reported hazard: CGMP Deviations: Lots recalled because they were manufactured at the same facility using the same components as the products that had cracked seals in caps that were found to be superpotent.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release